Robert Wieder

2.0k total citations
66 papers, 1.6k citations indexed

About

Robert Wieder is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Robert Wieder has authored 66 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Molecular Biology, 28 papers in Oncology and 16 papers in Cancer Research. Recurrent topics in Robert Wieder's work include Fibroblast Growth Factor Research (17 papers), Cancer Cells and Metastasis (12 papers) and Cancer, Hypoxia, and Metabolism (10 papers). Robert Wieder is often cited by papers focused on Fibroblast Growth Factor Research (17 papers), Cancer Cells and Metastasis (12 papers) and Cancer, Hypoxia, and Metabolism (10 papers). Robert Wieder collaborates with scholars based in United States, Israel and Netherlands. Robert Wieder's co-authors include Reju Korah, Qin Wang, Sylvia Christakos, Michael B. Shimkin, Eyal Fenig, Joachim Yahalom, Nabil R. Adam, Huisheng Wang, Qian Wang and Janice Gabrilove and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

In The Last Decade

Robert Wieder

66 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert Wieder United States 25 907 569 343 210 197 66 1.6k
Douglas C. Hixson United States 34 1.6k 1.8× 800 1.4× 350 1.0× 199 0.9× 156 0.8× 110 3.2k
George E. Durán United States 26 958 1.1× 860 1.5× 263 0.8× 227 1.1× 65 0.3× 54 1.7k
Nagarajan Kannan United States 27 1.0k 1.1× 783 1.4× 435 1.3× 143 0.7× 223 1.1× 57 1.8k
Jean‐Paul Brouillet France 21 800 0.9× 639 1.1× 615 1.8× 110 0.5× 246 1.2× 33 1.7k
James Watters United States 21 1.2k 1.4× 815 1.4× 400 1.2× 106 0.5× 237 1.2× 40 1.9k
Nan-Haw Chow Taiwan 27 1.4k 1.5× 507 0.9× 371 1.1× 166 0.8× 101 0.5× 69 2.4k
Hirobumi Teraoka Japan 32 2.4k 2.6× 655 1.2× 300 0.9× 235 1.1× 183 0.9× 109 3.0k
Karen S. Flatten United States 24 1.4k 1.6× 814 1.4× 226 0.7× 144 0.7× 131 0.7× 45 1.9k
Ashish Juvekar United States 11 804 0.9× 468 0.8× 316 0.9× 91 0.4× 92 0.5× 22 1.3k
Wei Cui United States 22 939 1.0× 519 0.9× 356 1.0× 167 0.8× 67 0.3× 86 1.8k

Countries citing papers authored by Robert Wieder

Since Specialization
Citations

This map shows the geographic impact of Robert Wieder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Wieder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Wieder more than expected).

Fields of papers citing papers by Robert Wieder

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Wieder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Wieder. The network helps show where Robert Wieder may publish in the future.

Co-authorship network of co-authors of Robert Wieder

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Wieder. A scholar is included among the top collaborators of Robert Wieder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Wieder. Robert Wieder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Adam, Nabil R. & Robert Wieder. (2024). Predictive Modeling of Long-Term Survivors with Stage IV Breast Cancer Using the SEER-Medicare Dataset. Cancers. 16(23). 4033–4033. 2 indexed citations
2.
Adam, Nabil R. & Robert Wieder. (2024). Temporal Association Rule Mining: Race-Based Patterns of Treatment-Adverse Events in Breast Cancer Patients Using SEER–Medicare Dataset. Biomedicines. 12(6). 1213–1213. 1 indexed citations
3.
Adam, Nabil R. & Robert Wieder. (2024). AI Survival Prediction Modeling: The Importance of Considering Treatments and Changes in Health Status over Time. Cancers. 16(20). 3527–3527. 3 indexed citations
4.
Wieder, Robert. (2024). Bone Marrow Stroma Co-cultivation Model of Breast Cancer Dormancy. Methods in molecular biology. 2811. 55–67. 1 indexed citations
5.
Wieder, Robert. (2023). Fibroblasts as Turned Agents in Cancer Progression. Cancers. 15(7). 2014–2014. 30 indexed citations
6.
Wieder, Robert. (2023). Awakening of Dormant Breast Cancer Cells in the Bone Marrow. Cancers. 15(11). 3021–3021. 6 indexed citations
7.
Wieder, Robert & Nabil R. Adam. (2023). Racial Disparities in Breast Cancer Treatments and Adverse Events in the SEER-Medicare Data. Cancers. 15(17). 4333–4333. 3 indexed citations
8.
Wieder, Robert & Nabil R. Adam. (2022). Drug repositioning for cancer in the era of AI, big omics, and real-world data. Critical Reviews in Oncology/Hematology. 175. 103730–103730. 16 indexed citations
9.
Wieder, Robert, Jeffrey L. Carson, & Brian L. Strom. (2020). <p>Restructuring of Academic Tracks to Create Successful Career Paths for the Faculty of Rutgers Biomedical and Health Sciences</p>. Journal of Healthcare Leadership. Volume 12. 103–115. 4 indexed citations
10.
Lü, Haiyan, et al.. (2018). Reawakening of dormant estrogen-dependent human breast cancer cells by bone marrow stroma secretory senescence. Cell Communication and Signaling. 16(1). 48–48. 54 indexed citations
11.
Kumar, Rajan, Sri HariKrishna Vellanki, Robin M. Smith, & Robert Wieder. (2012). Determination of single cell surface protein expression using a tagless microfluidic method. Lab on a Chip. 12(9). 1646–1646. 1 indexed citations
12.
Wieder, Robert, et al.. (2009). Dual FGF-2 and Intergrin α5β1 Signaling Mediate GRAF-Induced RhoA Inactivation in a Model of Breast Cancer Dormancy. Cancer Microenvironment. 2(1). 33–47. 30 indexed citations
13.
Bryan, Margarette, et al.. (2008). Influence of Prescription Benefits on Reported Pain in Cancer Patients. Pain Medicine. 9(8). 1148–1157. 9 indexed citations
14.
Korah, Reju, et al.. (2006). Coordinate loss of fibroblast growth factor 2 and laminin 5 expression during neoplastic progression of mammary duct epithelium. Human Pathology. 38(1). 154–160. 25 indexed citations
15.
Korah, Reju, et al.. (2004). Role of RhoA in survival of dormant breast cancer cells.. Cancer Research. 64. 563–564. 2 indexed citations
16.
Wang, Qin & Robert Wieder. (2004). All-trans retinoic acid potentiates Taxotere-induced cell death mediated by Jun N-terminal kinase in breast cancer cells. Oncogene. 23(2). 426–433. 48 indexed citations
17.
Wieder, Robert, Steven Novick, Bruce W. Hollis, et al.. (2003). Pharmacokinetics and safety of ILX23-7553, a non-calcemic-vitamin D3 analogue, in a phase I study of patients with advanced malignancies. Investigational New Drugs. 21(4). 445–452. 15 indexed citations
18.
Wang, Qin, Paul Maloof, Huisheng Wang, et al.. (1998). Basic Fibroblast Growth Factor Downregulates Bcl-2 and Promotes Apoptosis in MCF-7 Human Breast Cancer Cells. Experimental Cell Research. 238(1). 177–187. 57 indexed citations
19.
Wieder, Robert, Huisheng Wang, Qin Wang, et al.. (1997). Low Level Expression of Basic FGF Upregulates Bcl-2 and Delays Apoptosis, But High Intracellular Levels are Required to Induce Transformation in NIH 3T3 Cells. Growth Factors. 15(1). 41–60. 32 indexed citations
20.
Wieder, Robert, Vivian Barak, & Z Ben-Ishay. (1995). High-Efficiency Retroviral Gene Transfer into Murine High-Proliferative-Potential Cells Cycle-Activated by Cytosine Arabinoside. Human Gene Therapy. 6(7). 865–871. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Douglas C. Hixson Breakdown of academic impact, for papers by George E. Durán Breakdown of academic impact, for papers by Nagarajan Kannan Breakdown of academic impact, for papers by Jean‐Paul Brouillet Breakdown of academic impact, for papers by James Watters Breakdown of academic impact, for papers by Nan-Haw Chow Breakdown of academic impact, for papers by Hirobumi Teraoka Breakdown of academic impact, for papers by Karen S. Flatten Breakdown of academic impact, for papers by Ashish Juvekar Breakdown of academic impact, for papers by Wei Cui
Rankless by CCL
2026